BEIJING, China I February 03, 2021 I InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today the first subject dosed in clinical trial of pan-FGFR inhibitor ICP-192 in the United States.
ICP-192 is a highly selective small-molecule pan-FGFR inhibitor for the treatment of various solid tumors with FGFR aberrations. Currently it is in Phase I/II clinical studies in China and the United States.
The Phase II trial in China is a multi-center, open-label clinical trial designed to evaluate the safety and efficacy of ICP-192 in patients with advanced cholangiocarcinoma and urothelial cancer that have FGFR aberrations. The phase II clinical trials have enrolled nearly 20 patients, and cases of partial response and complete response have been observed in patients of FGFR gene alterations.
“We will continue to advance ICP-192 in clinical studies for the treatment of advanced solid tumors with FGFR aberrations in China and global,” said Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare. “ICP-192 is an excellent drug candidate for the treatment of solid tumors with FGFR aberrations. We will work together with top clinical experts to rapidly advance the trials to explore the potential usage of ICP-192 in a variety of solid tumors. We hope to provide patients with better treatment options.”
ICP-192 is the second innovative drug candidate discovered by InnoCare, which was approved for the initiation of clinical trials in the U.S.
About InnoCare
InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey, and Boston.
SOURCE: InnoCare
Post Views: 257
BEIJING, China I February 03, 2021 I InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today the first subject dosed in clinical trial of pan-FGFR inhibitor ICP-192 in the United States.
ICP-192 is a highly selective small-molecule pan-FGFR inhibitor for the treatment of various solid tumors with FGFR aberrations. Currently it is in Phase I/II clinical studies in China and the United States.
The Phase II trial in China is a multi-center, open-label clinical trial designed to evaluate the safety and efficacy of ICP-192 in patients with advanced cholangiocarcinoma and urothelial cancer that have FGFR aberrations. The phase II clinical trials have enrolled nearly 20 patients, and cases of partial response and complete response have been observed in patients of FGFR gene alterations.
“We will continue to advance ICP-192 in clinical studies for the treatment of advanced solid tumors with FGFR aberrations in China and global,” said Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare. “ICP-192 is an excellent drug candidate for the treatment of solid tumors with FGFR aberrations. We will work together with top clinical experts to rapidly advance the trials to explore the potential usage of ICP-192 in a variety of solid tumors. We hope to provide patients with better treatment options.”
ICP-192 is the second innovative drug candidate discovered by InnoCare, which was approved for the initiation of clinical trials in the U.S.
About InnoCare
InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey, and Boston.
SOURCE: InnoCare
Post Views: 257
